JOURNAL ARTICLE

[SGLT2 inhibitor or GLP-1 receptor agonist in a type 2 diabetic patient with cardiovascular disease ?]

André J Scheen, Nicolas Paquot
Revue Médicale Suisse 2018 August 22, 14 (615): 1460-1465
30136462
Sodium-glucose cotransporter type 2 inhibitors (SGLT2is), with empagliflozin in EMPA-REG OUTCOME, and glucagon-like peptide-1 receptor agonists (GLP-1RAs), with liraglutide in LEADER, have proven their ability to reduce major cardiovascular events and mortality in patients with type 2 diabetes and established cardiovascular disease. Thus clinicians have to choose between the two options in patients at high risk. The choice should be based upon a personalized approach, which has to take into account the drug properties, especially the tolerance profile, and patient's individual characteristics. In patients with heart failure, the added value of a SGLT2i appears obvious while in those with advanced renal insufficiency, current evidence favours the use of a GLP-1RA.

Full Text Links

Find Full Text Links for this Article

Discussion

You are not logged in. Sign Up or Log In to join the discussion.

Related Papers

Remove bar
Read by QxMD icon Read
30136462
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"